Summary
The loss of central nicotinic receptors is a neurochemical hallmark of several degenerative brain disorders, notably Alzheimer’s (AD) and Parkinson’s disease (PD). However, uncertainty has remained about the significance of this loss for the cognitive symptomatology of these disorders. Investigations of the effects of nicotinic agents in both normal and diseased individuals have led to important information about the role of nicotinic systems in cognitive functioning. These studies suggest that amelioration of some of the cognitive disturbances in AD and PD may be possible utilizing nicotinic compounds.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Schwartz R. Autoradiographic distribution of high affinity muscarinic and nicotinic cholinergie receptors labeled with [[3H]acetylcholine in rat brain. Life Sciences 1986; 38: 2111–2119.
Whitehouse P, Martino A, Antuono P, Kellar K. Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 1986; 371: 146–151.
Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinsons’s diseases. J Neurochem 1992; 58: 529–541.
Weingartner H, Cohen R, Sunderland T, Tariot P, Thompson K, Newhouse P. Diagnosis and assessment of cognitive dysfunctions in the elderly. in Melzer H (ed), Psychopharmacology, the Third Generation of Progress. New York, Raven Press, 1987: 909–919.
Martin BR, Onaivi ES, Martin TJ. What is the nature of mecamylamine’s antagonism of the central effects of nicotine? Biochem Pharmacol 1989; 38: 3391–3397.
Newhouse P, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacol 1994; l0: 93–107.
Thompson D. Repeated acquisition as a behavioral base line for studying drug effects. J Pharmacol Exp Ther 1973; 184: 506–514.
Corwin J, Peselow E, Fieve R, Rotrosen J. Memory in untreated depression: severity and task requirement effects. Presented at ACNP Annual Meeting, December, San Juan 1987.
Thome D, Genser S, Sing H, Hegge F. The Walter Reed performance assessment battery. Neurobehav Toxicol Teratol 1985; 7: 415–418.
Newhouse P, Sunderland T, Tariot P, Blumhardt CL, Weingartner H, Mellow A, Murphy DL. Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacol 1988; 95: 171–175.
Newhouse P, Sunderland T, Narang P, Mellow AM, Fertig JB, Lawlor BA, Murphy DL. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and patients with Alzheimer’s disease. Psychoneuroendocrin 1990; 15: 471–484.
Newhouse P.A. Cholinergic drug studies in dementia and depression. Advan Exp Med Biol 1990; 282: 65–76.
Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacol 1992; 108: 485–494.
Warburton DM, Wesnes K, Shergold JM. Facilitation of learning and state dependency with nicotine. Psychopharmacol 1986; 89: 55–59.
Colrain IM, Mangan GL, Pellet OL, Bates TC. Effects of post-learning smoking on memory consolidation. Psychopharmacol 1992; 108: 448–451.
Court JA, Piggott MA, Perry EK, Barlow RB, Perry RH. Age associated decline in high-affinity nicotine binding in human brain frontal-cortex does not correlate with the changes in choline-acetyltransferase activity. Neurosci Res Comm 1992; 10: 125–133.
Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on tolerance development and nicotine receptors. J Pharmacol Exp Ther 1983; 226: 817.
Arneric SP, Sullivan JP, Decker MW, Brioni JD, Buccafusco JJ, Briggs CA, Donnelly-Roberts D, Williams M. Cholinergic Channel Activators (ChCAs) as therapeutics for CNS disorders: ABT 418 as a prototype ChCA to treat Alzheimer’s disease. Neuropsychopharm 1994; 10 (3S): 395S.
Meyer EM. A nicotinic approach for neuroprotection and memory enhancement: studies with anabaseine derivatives. Neuropsychopharmacol 1994; 10 (3S): 393S.
Newhouse PA, Potter A, Lenox RH. The effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimer’s and Parkinson’s Diseases. Med Chem Res 1993, 2: 628–642.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Birkhäuser Verlag Basel
About this chapter
Cite this chapter
Newhouse, P.A., Potter, A., Piasecki, M., Geelmuyden, J., Corwin, J., Lenox, R. (1995). Nicotinic Modulation of Cognitive Functioning in Humans. In: Clarke, P.B.S., Quik, M., Adlkofer, F., Thurau, K. (eds) Effects of Nicotine on Biological Systems II. Advances in Pharmacological Sciences. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7445-8_45
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7445-8_45
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-0348-7447-2
Online ISBN: 978-3-0348-7445-8
eBook Packages: Springer Book Archive